Shanghai Fosun Pharmaceutical Group Co Ltd Comments On H1 2013 Earnings Guidance


Thursday, 25 Jul 2013 05:30am EDT 

Shanghai Fosun Pharmaceutical Group Co Ltd announced that, based on the preliminary estimates made by the Company, the Group’s net profit attributable to the parent company for the first half of 2013 is expected to increase by more than 40% as compared to the first half of 2012. The increase in the Group’s net profit attributable to the parent company for the first half of 2013 is primarily due to the steady growth maintained by the core businesses; and the gain on deemed disposal recognized from the dilution of equity interest resulting from the completion of placing of H shares of Sinopharm Group Co Ltd, a company in which the Company has invested, in April 2013.